WS #15522
Corporate activity remains active with Viatris agreeing to acquire Pacira BioSciences for $1.65B, signaling consolidation in the pharmaceutical sector. Earnings results were mixed: PepsiCo beat EPS estimates but trimmed guidance, leading to a choppy market reaction, while Tilray posted a revenue miss as cannabis sales declined. Hyperfine saw its shares jump 9% on positive Q3 revenue guidance. These results highlight a cautious corporate outlook, with companies focusing on cost management and margin defense rather than aggressive growth.
Corporate Earnings & M&A Activity
Corporate activity remains active with Viatris agreeing to acquire Pacira BioSciences for $1.65B, signaling consolidation in the pharmaceutical sector. Earnings results were mixed: PepsiCo beat EPS estimates but trimmed guidance, leading to a choppy market reaction, while Tilray posted a revenue miss as cannabis sales declined. Hyperfine saw its shares jump 9% on positive Q3 revenue guidance. These results highlight a cautious corporate outlook, with companies focusing on cost management and margin defense rather than aggressive growth.